GTx's Enobosarm fails in two late-stage trials

|By:, SA News Editor

GTx's (GTXI) Enobosarm drug for non-small cell lung cancer failed to meet its primary endpoints regarding lean body mass (LBM) and physical function in two Phase III studies.

However, Enobosarm did demonstrate "significant quantitative advantage in LBM compared to placebos in both trials."

GTx intends to hold talks with the FDA and EU regulators about the company's next steps. (PR)